Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press62910.36691/RJA629ArticlesСтатьиResearch ArticleEMOLLIENT MILK XEMOSE IN THERAPY OF ATOPIC DERMATITIS IN CHILDRENПРИМЕНЕНИЕ МОЛОЧКО-ЭМОЛЬЯНТА КСЕМОЗ В ТЕРАПИИ АТОПИЧЕСКОГО ДЕРМАТИТА У ДЕТЕЙKINDEEVAE TКИНДЕЕВАЕ Тekindeeva@bk.ruKOROTKIIN GКОРОТКИЙН ГPAMPURAA NПАМПУРАА НRussian National Research Medical University named after N.I. PirogovГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России15082014114NO4 (2014)№4 (2014)596310032020Copyright ©; 2014, Pharmarus Print MediaCopyright ©; 2014, Фармарус Принт Медиа2014Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/629

Background. Structural and functional damages of the epidermal barrier in patients with atopic dermatitis promote the entry of allergens and development of Th2-type allergic inflammation. Moisturizers containing lipids increase the physiological antiinflammatory effects of topical corticosteroids (TGKS), improve the epidermal barrier and reduce the duration of TGKS using preventing further infringement barrier. To evaluate the clinical efficacy of emollient milk Xemose in children with atopic dermatitis. Materials and methods. We examined 27 children with atopic dermatitis. Children were divided into 2 groups: patients in group 1 (n=14) used emollient milk Xemose twice a day on the skin lesions and limbs in the complex therapy, patients in the 2nd group (n=13) received combined therapy incorporating traditional dampening agents on the basis of lanolin (Unna cream) 3 times daily. All patients underwent measurement of transepidermal water loss (TEWl) (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (Skin-pH-Meter, Multi Probe Adapter MPA 5/9, Courage + Khazaka) before and after 2 weeks of therapy. Results. Patients in groupthat used Xemose milk and children in group with Unna cream after 2 weeks showed a statistically significant decrease of TEWl (p=0,041 and p=0,04, respectively). TEWl was significantly lower in children treated for 2 weeks with milk Xemose (p=0,027) than in children treated with Unna cream. in both groups pH skin surface have not changed (р=0,22 and р=0,22 respectively). Conclusion. Clinical efficacy of milk Xemose as compound improving skin barrier function in children with atopic dermatitis was shown.

Цель. Оценить клиническую эффективность использования молочко-эмольянта ксемоз у детей с атопи- ческим дерматитом (атд). Материалы и методы. обследованы 27 детей с атд. дети были разделены на 2 группы: пациенты 1-й группы (n=14) использовали молочко ксемоз 2 раза в день на очаги поражения кожи лица и конечностей в составе комплексной терапии; пациенты 2-й группы (n=13) получали комплексную терапию с включением традиционного увлажняющего средства на основе ланолина (крем унны) 3 раза в день. всем пациентам выполнено измерение в очаге воспаления транс-эпидермальной потери воды (тэПв) (Tewameter тм 300, Multi Probe Adapter MPA 5/9, Courage+Khazaka) и рН поверхности кожи (Skin-pH-Meter, Multi Probe Adapter MPA 5/9, Courage+Khazaka) до начала терапии и через 2 нед на фоне терапии. Результаты. в группе детей, получавших комплексную терапию с включением молочка ксемоз, и в группе детей, использовавших крем унны, через 2 нед тэПв достоверно снизилась (р=0,041 и р=0,04 со- ответственно). тэПв у детей, получавших в течение 2 нед молочко ксемоз, достоверно ниже (р=0,027) по сравнению с детьми, получавшими традиционное увлажняющее средство (крем унны). в группах детей рН поверхности кожи не изменилась (р=0,22 и р=0,22 соответственно). Заключение. Показана клиническая эффективность в восстановлении кожного барьера молочка ксемоз у детей с атд.

atopic dermatitisepidermal barriertransepidermal water lossskin pHатопический дерматитэпидермальный барьертрансэпидермальная потеря водырН кожимолочко ксемозSaijic D., Asiniwasis R., Skotnicki-Grant S. A look at epi- dermal barrier function in atopic dermatitis: Physiologic lipid replacement and the role of ceramide. Skin Therapy Lett. 2012, v. 7, р. 6-9.Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol. Rev. 2011, v. 242, р. 233-246.Elias P.M., Wood L.C., Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. American Journal of Contact Dermatitis. 1999, v. 10, р. 119-126.Taïeb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis. 1999, v. 41, р. 177-180.Elias P., Feingold K., Fluhr J. The skin as an organ of protec- tion. In Dermatology in General Medicine. Friedberg I.M., Eisen A.Z., Wolff K. et al. editors. New York. 2003, р. 107-118.Madison K.C. Barrier function of the skin: «la raison d`etre» of the epidermis. J. Invest. Dermatol. 2003, v. 121, р. 231-241.Fluhr J.W., Kao J., Jain M. et al. Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J. Invest. Dermatol. 2001, v. 117, р. 44-51.Lee Y.B., Park H.J., Kwon M.J. et al. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur. J. Dermatol. 2011, v. 21, р. 710-716.Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J. Drugs Dermatol. 2009, v. 8, р. 1106-1111.Elias P.M. Barrier-repair therapy for atopic dermatitis: cor- rective lipid biochemical therapy. Expert Rev. Dermatol. 2008, v. 3, р. 441-452.Akdis C., Akdis M., Bieber T. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology. American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. J. Allergy. Clin. Immunol. 2006, v. 118, р. 152-169.Белоусова Т.А., Горячкина М.В. Современные пред- ставления о структуре и функции кожного барьера и терапевтические возможности коррекции его нарушений. Рус. мед. журн. 2004, № 8, c. 14-18.Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am. J. Clin. Dermatol. 2003, v. 4, р. 771-188.Sato J., Denda M., Chang S. et al. Abrupt decreases in environ- mental humidity induce abnormalities in permeability barrier homeostasis. J. Invest. Dermatol. 2002, v. 119, р. 900-904.De Benedetto A., Kubo A., Beck L.A. Skin Barrier Disrup- tion - A Requirement for Allergen Sensitization? J. Invest. Dermatol. 2012, v. 132, р. 949-963.Elias P.M., Ahn S.K., Denda M. et al. Modulations in epider- mal calcium regulate the expression of differentiation-specific markers. J. Invest. Dermatol. 2002, v. 119, р. 1128-1136.Hachem J.P., Crumrine D., Fluhr J. et al. pH directly regu- lates epidermal permeability barrier homeostasis and stratum corneum integrity cohesion. J. Invest. Dermatol. 2003, v. 121, р. 345-353.Ramachandran R., Hollenberg M.D. Proteinases and signa- ling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 2008, v. 153. р. 263-282.Wood L. C., Elias P. M., Calhoun C. et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J. Invest. Dermatol. 1996, v. 106, р. 397-403.Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J. Allergy Clin. Immunol. 2008, v. 121, р. 1337-1343.Mauro T., Holleran W.M., Grayson S. et al. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch. Dermatol. Res. 1998, v. 290, р. 215-222.Ohman H., Vahlquist A. The pH gradient over the stratum corneum differs in X-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the «acid skin mantle»? J. Invest. Dermatol. 1998, v. 111, р. 674-677.Hachem J.P., Man M.Q., Crumrine D. et al. Sustained serine proteases activity by prolonged increase in pH leads to degra- dation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J. Invest. Dermatol. 2005, v. 125, р. 510-520.Hachem J.P., Fowler A., Behne M. et al. Increased stratum corneum pH promotes activation and release of primary cy- tokines from the stratum corneum attributable to activation of serine proteases. J. Invest. Dermatol. 2002, v. 119. р. 258.